Pfizer's tasocitinib meets psoriasis endpoint

Pfizer Inc. (NYSE:PFE) said oral tasocitinib met the primary endpoint of a significantly greater proportion of patients achieving a PASI 75 response at week 12 vs. placebo in a Phase II trial to treat...